2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Pathogens Infection
  5. Gastroenteritis

Gastroenteritis

Gastroenteritis is an acute infection of the gastrointestinal tract caused by various pathogens, presenting with diarrhea and/or vomiting, often accompanied by fever, abdominal pain, and systemic symptoms. Nontyphoidal Salmonella is a common cause, leading to an incubation period of 6–72 hours (mean 24 hours), followed by abrupt onset of nausea, vomiting, cramping abdominal pain, and watery or bloody diarrhea. Fever occurs in about 70% of cases, with abdominal tenderness and fecal leukocytes or occult blood. Mild leukocytosis with a left shift is typical. Symptoms usually resolve within a week in healthy children, but may persist for weeks in neonates, young infants, and immunocompromised individuals, including those with AIDS, where disseminated infection, shock, and death may occur. In patients with inflammatory bowel disease, particularly active ulcerative colitis, Salmonella infection can lead to severe complications such as bowel wall invasion, toxic megacolon, and systemic toxicity. Reactive arthritis, associated with HLA-B27, develops in 2% of cases, mainly in adolescents and adults. Fecal shedding of Salmonella can continue for a median of 7 weeks after symptom resolution, especially prolonged in children under 5 years of age.

Gastroenteritis (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N4280
    7,8-Dimethoxycoumarin 2445-80-9 99.75%
    7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H+/K+-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis.
    7,8-Dimethoxycoumarin
  • HY-183651
    15-PGDH-IN-5 1714984-32-3
    15-PGDH-IN-5 (compound 5) is a sulfoxide-derived 15-PGDH inhibitor. 15-PGDH-IN-5 exhibits higher metabolic stability and superior in vivo exposure compared with the lead compound SW033291 (HY-16968). 15-PGDH-IN-5 inhibits the irreversible oxidative catabolism of PGE2 by 15-PGDH, thereby enhancing the tissue-specific bioavailability of endogenous PGE2. 15-PGDH-IN-5 exerts anti-inflammatory effects and accelerates tissue repair and regeneration, and it is used in studies on tissue injury and fibrosis-related diseases such as inflammatory bowel disease and idiopathic pulmonary fibrosis.
    15-PGDH-IN-5
  • HY-123925
    CSLP43 2244988-80-3
    CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease.
    CSLP43
  • HY-178727
    R 58639 99157-83-2
    R 58639 is a histamine H1 receptor antagonist. R 58639 can be used for the study of gastric ulcers.
    R 58639